DARZALEX FASPRO®
(daratumumab and hyaluronidase-fihj)
Medical inquiries
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)
Medical Information
TRIMM-2 (MMY1002) Study - TALVEY and DARZALEX
Last Updated: 07/22/2025
Summary
A summary of this response is provided as an interactive PDF (iPDF) that can be accessed by clicking the following link:
- TALVEY®
(talquetamab-tgvs) - TRIMM-2 (MMY1002) Study - TALVEY and DARZALEX FASPRO ± Pomalidomide Cohort - Minimum requirement to access interactive content: Adobe Acrobat Reader
- The executive summary infographic of the iPDF content is provided below
PRODUCT LABELING
- TALVEY (talquetamab-tgvs). [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TALVEY-pi.pdf.
- DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf.
Endchat
Chat live